AstraZeneca

2021 was a year of supply chain disruptions and big stock market floats

Study suggests a protein in the blood is attracted to a key part of the vaccine

Experts question claim that Oxford-developed jab has saved Britain from Europe’s high hospitalisation rates

Trial finds injection reduces risk of symptomatic infection by 83%

Downing Street accused French manufacturer of breaching contract

Experts voice fears over England’s lockdown-lifting ‘experiment’

Pascal Soriot’s bonus might be deserved, but that doesn’t mean it’s necessarily wise

Ireland’s health minister confirms that Brussels is considering a possible lawsuit over delivery shortfall

Experts say odds of adverse side effect are about same as ‘being hit in your home by crashing aeroplane’

UK regulator says evidence of a link between the jab and very rare blood clot is ‘firming up’

Figures suggest that quicker vaccine rollouts are pay to play

Government officials keen to avoid ‘war of words’ with Indian government over delivery hold-up

Tensions over Covid vaccine supplies have escalated into a battle of words between Brussels and London after Ursula von der Leyen threatened to use em…

Jewel in the crown of the UK jab campaign has faced harsh scrutiny in Europe

European safety concerns over vaccine remain despite positive data from UK campaign

Pharmaceutical boss denies claim doses have been sold to higher bidder

Fresh setback to bloc’s bid to inoculate 70% of adults by summer

AstraZeneca failed to disclose that under-55s made up test group in which jab was most effective

Team behind university’s Covid jab admit the 90% effective dosage was discovered by mistake

Latest trial results show the university’s jab is up to 90% effective

Leaked report says volunteer in UK was left unable to walk after receiving two doses

Researchers working to develop the world’s first Covid-19 vaccine explain how it is being done

Results of first human tests fuel hopes that jab may be rolled out by Christmas

Scientists from university-led team say their jab may offer ‘double defence’ against coronavirus

AstraZeneca claims £55-per-share bid undervalues the company and carries a 'big execution risk'

Cosseting national champions isn’t the British way. But is it time to make an exception